Iterative advancements in diabetes technology including lower basal glucose targets and several active insulin time settings that personalize AID (4, 16–19) have been integral to improved HbA1c and CGM-derived glucose metrics (20–22), physiological normalization (23, 24), and better psychosocial outcomes (16, 18, 25). This evidence concerns the gene INS and diabetes mellitus.